Hatmopit you obviously never had to work in a lad study with hamsters! ha ha they hate handling get very stressed easily , two could have been excluded for so many medical reasons showing weaker metabolisms down to even ovulation cycle they have very small nose orifices and limited sinus cavity the dosages were very dilute x10 below probable top line efficacy but still despite all the above issues showed plus 90 pct reduction in active virus in a few days a great if not outstanding result this is a preliminary exercise to the ferret trial much easier to work with more virile and long past tested ferrets as really good animal co horts for this type of trial - indeed, there are quite a few major medical research labs currently using this gold standard process world wide i expect quite a significant outcome from that recce o/s trial which is being conducted on several avenues for delivery for efficacy comparisons- in addition we will likely have the Australian based csiro/Dougherty inst. trial results to offer comparative efficacy data despite being on different processes of administration - not only that we should be able to look to other trials being conducted contemporaneously worldwide for comparative assessment, but likely be able to see recce performance against best in class alternative drug options being pursued to try and hold and defeat covid on therapy for infected individuals
next year - quite early i think in quarter one . we should see these greatly anticipated results released on a full and deep data analysis
big big 2021 coming on four fronts for recce
RCE Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)